Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

@AliakbarAbolha1 @Sina_Thr https://t.co/WRBAWmyniQ

Psilocybin CAN help depression. https://t.co/M9Ipdq8fJs

@SnippyLady @Miles_Tarbox @caravsx Miles point is certainly valid. See https://t.co/UhEHE7qrvJ. In fairness, one must consider with a critical mindset. It's promising but no panacea. Nothing is with mental illness.

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - ScienceDirect https://t.co/z4efIxjd2t

@joarhalvorsen @H_Grostad 1. Personer med behandlings-resistent depresjon viser en tydelig forbedring etter inntak av psilocybin i en terapeutisk kontekst. https://t.co/oANcaeHw3U

@MJA_Editor 1st ep covers psilocybin (magic mushrooms), Open-label study with people whose depression had failed to respond to standard treatments showed some improvements ...more research needed but a topic worthy of investigation? disclaimer i haven't se

RT @pharmacoeeg: Open-Label Trial showing Efficiancy of Psylocibin in the Treatment of Depression: https://t.co/H7xdEtH6Ea and https://t.co…

@andreas_wahl @dagfinnhessenp " Relative to baseline, depressive symptoms were markedly reduced 1 week (mean QIDS difference –11·8, 95% CI –9·15 to –14·35, p=0·002, Hedges’ g=3·1) and 3 months (–9·2, 95% CI –5·69 to –12·71, p=0·003, Hedges’ g=2) after high

https://t.co/CJn1zp4E5a

RT @emigrl: ランセットのマジックマッシュルームを使った鬱病治療の報告これね https://t.co/zGUcDzhbtB まだまだ研究が必要だけど、期待ができる。

RT @m_wall: @AllenFrancesMD @neuroraf Perhaps you'd consider trying psychedelic-assisted psychotherapy first? Very effective (early days fo…

@AllenFrancesMD @neuroraf Perhaps you'd consider trying psychedelic-assisted psychotherapy first? Very effective (early days for trials, but it's hopeful) and less invasive/fewer side effects. https://t.co/XSbNiY5SIy

@Okiedokie02 https://t.co/UexIPS4v3G

Psilocybin with psychological support for treatment-resistant depressi... https://t.co/UexIPS4v3G

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study https://t.co/8slH3An63y @TessTsindos #Sphpm

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

@MAPSCanada @RCarhartHarris @ProfDavidNutt @MendelKaelen Full-text pdf: https://t.co/nb2IXtnOU4 @Chacruna_net @hellopsillow @APRA_bot @BeckleyResearch

RT @MAPSCanada: #Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility,…

#Psilocybin with psychological support for treatment-resistant #depression: open-label study, investigates the feasibility, safety & efficacy in patients with treatment-resistant depression. #BeckleyImperial @RCarhartHarris @ProfDavidNutt @MendelKaelen

Eens ✅ Maar... wél onder begeleiding, en niet voor de meute!

@strvrw @Merlijn65761540 @Vera_Bergkamp Drugs kunnen best geschikt zijn voor mensen. Zie bijv. https://t.co/1M0SIECroU, https://t.co/NIgrnuckGf, en https://t.co/uCMMN45apA. Onderzoek wordt zwaar belemmerd door de juridische status, ondanks veelbelovendheid

Psilocybin with psychological support for treatment-resistant depressi... https://t.co/Nbn1NJZ5eV

Researchers suggest removing schedule 1 classification for Psilocybin #Magic #mushroom https://t.co/WobeJBjJJh Quick pub med shows potential for: #treatment resistant #depression #PTSD #OCD #scicomm https://t.co/vNMZWtO39Z https://t.co/drUG5pQNQg http

@drkeithscott John Hopkins researchers suggest removing schedule 1 classification for #Magic #mushroom https://t.co/WobeJBjJJh Quick pub med shows potential for: #treatment resistant #depression #PTSD #OCD #scicomm https://t.co/vNMZWtO39Z https://t.co/

Jokes aside https://t.co/UeuYRLf7FJ

@AOC Thank you @AOC Psilocybin with psychological support for treatment-resistant depressi... https://t.co/IiIVdIy4bc

Sounds radical and I can imagine it feeding into culture warring but it's just eminently sensible policy, with further research more than supported by the evidence (e.g. https://t.co/gWbORzId4A; https://t.co/4pErdYOeRq; https://t.co/gn71Fr2NLU)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study https://t.co/htBd5IS1Rn

@pinkyrosin https://t.co/9c7s7rwKDb

The open access Lancet Psych article is here: https://t.co/20Sf7Hbspb

@AntLiveOfficial @TheLSDBlotter So much research going on. I was at a talk by ketamine researchers a few weeks ago; they are doing therapy and research and about to release a second book about it. This research from 2016 on psilocybin & depression is r

Cogumelos psicodélicos apresentam ótimos resultados contra sintomas de depressão. ❤️🍄 #psychedelic #freelula #mariellefranco #depression https://t.co/yh5f7HunZ0

RT @NicholasJohn83: John Hopkins researchers suggest removing schedule 1 classification for #Magic #mushroom https://t.co/WobeJBjJJh Quick…

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @NicholasJohn83: John Hopkins researchers suggest removing schedule 1 classification for #Magic #mushroom https://t.co/WobeJBjJJh Quick…

John Hopkins researchers suggest removing schedule 1 classification for #Magic #mushroom https://t.co/WobeJBjJJh Quick pub med shows potential for: #treatment resistant #depression #PTSD #OCD #scicomm https://t.co/vNMZWtO39Z https://t.co/drUG5pQNQg ht

RT @annatessrickman: @CharlesFLehman @LeoBeletsky @RCarhartHarris @TEDx https://t.co/ui78zPgNwB

RT @DayanaHappyBody: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - The Lancet…

RT @HaKoSeMi: 面白い論文。匙加減次第で毒にも薬にもなるって医学らしくていいですね。 https://t.co/Z44w626iUh

RT @HaKoSeMi: 面白い論文。匙加減次第で毒にも薬にもなるって医学らしくていいですね。 https://t.co/Z44w626iUh

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @DayanaHappyBody: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - The Lancet…

RT @HaKoSeMi: 面白い論文。匙加減次第で毒にも薬にもなるって医学らしくていいですね。 https://t.co/Z44w626iUh

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @HaKoSeMi: 面白い論文。匙加減次第で毒にも薬にもなるって医学らしくていいですね。 https://t.co/Z44w626iUh

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

寛解って事は摂取し続けなければならないのか？

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

面白い論文。匙加減次第で毒にも薬にもなるって医学らしくていいですね。

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

RT @Kztk_2: マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

マジックマッシュルームの成分であるPsilocybinを、治療抵抗性のうつ病患者へ投与したところ、３週間後に寛解に達したというlancet掲載論文。 https://t.co/eM37nFg5VV

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - The Lancet Psychiatry ⁦@tferriss⁩ https://t.co/4ef3MBrbMc

@CharlesFLehman @LeoBeletsky @RCarhartHarris @TEDx https://t.co/ui78zPgNwB

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - The Lancet Psychiatry https://t.co/CAJKPpg8kd

RT @KyYaYa1970: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - The Lancet Psyc…

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study - The Lancet Psychiatry. ScienceDirect https://t.co/4KTevjhQHk

Psilocybiiniä testattiin laajempaa kliinistä tutkimusta varten. 12 depressiosta kärsivästä osanottajasta psilocybiini näytti tehoa 1 viikko hoidon jälkeen, ja suurin osa 3kk hoidosta. https://t.co/CfPc47Q1wU

RT @PrivilegeHealth: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. https://t.c…

RT @PrivilegeHealth: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. https://t.c…

"Breakthrough" is misleading. The study from 2015: https://t.co/EGzuz3yPq1 was an unblinded open-study with only 12-subjects and no control group. Open studies are subject to bias when the evaluation points are subjective. Hype needs to be tempered. Us:

RT @PrivilegeHealth: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. https://t.c…

RT @PrivilegeHealth: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. https://t.c…

@isidorspappa @CarlitoYgdrasil "Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred." https://t.co/2cnUYZAry7

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. https://t.co/EkvJpgYrXo

RT @JustinCaouette: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study https://t.co/…

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study https://t.co/4pWo41ctVt

RT @Entheogenist: @Chacruna_net https://t.co/t0RZGeQZ02

RT @Entheogenist: @PsydelicsToday https://t.co/t0RZGeQZ02

@PsydelicsToday https://t.co/t0RZGeQZ02

@Chacruna_net https://t.co/t0RZGeQZ02

@Hey_Theist https://t.co/EmOuVrW95w

@Hey_Theist Also look at Psilocybin: https://t.co/EmOuVrW95w

https://t.co/4G5ydfiw7f https://t.co/eIODiUrreb https://t.co/u0x4rY3Y5l https://t.co/Iu1DB5dUfN

This is the paper about the trial https://t.co/Gb685YI5kn

Although a very small feasibility study w/ no control group, a response rate of 67% for treatment-resisistent depression just 1 week after psilocybin administration (58% continued to meet response criteria at 3 months) is impressive. 1/ https://t.co/mdNdNW

@elizalitotes @mariskreizman Here https://t.co/WQtBiK6O67 https://t.co/def3xZMKkr https://t.co/1gEWrO7Seb There are a ton of other clinical studies going on using psilocybin for mental health issues with tons of promise, and there is a ton of anecdot

RT @AmeerRosic: These findings build on top of other promising results looking at specific hallucinogenic substances (LSD, psilocybin) prom…

These findings build on top of other promising results looking at specific hallucinogenic substances (LSD, psilocybin) promoting meaningful improvements in depression. https://t.co/apWFojfsci

This scientific study provides preliminary support for the safety and efficacy of psilocybin for... https://t.co/2GkBEwo2xF

@aSpaceCadette I have colleagues that are interested in this research / advocacy. There is some research in it, but it difficult to establish a good protocol when something is schedule 1... https://t.co/zg1HhEfiCk

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. | PubMed https://t.co/XQEdeFg6tH

Comin' thru with the refs too. PULLIN RECEIPTS. https://t.co/7y4ucAnXI3, https://t.co/DacBVq5Cug

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study https://t.co/EZ5o2LAuCN

@newscientist #Psilocybin acts as "lubricant for the mind" allowing people to escape a cycle of depressive symptoms. 🍄🎭 https://t.co/fpfufEh7oX

#Psychedelic compound #psilocybin may have therapeutic potential in treatment resistant #depression. https://t.co/o48XPwDZ93

'prelim support for Psilocybin use in Treatment-Resistant Depression' in @TheLancetPsych https://t.co/qF0Wqn1Dos